natgillin/translations-raw huggingface dataset:
Like all vaccines, Ervebo can cause side effects, although not everybody gets them.
Kot vsa cepiva ima lahko tudi cepivo Ervebo neželene učinke, ki pa se ne pojavijo pri vseh cepljenih osebah.
Protocol 010 (Ring vaccination study) was a Phase 3 open-label cluster-randomized trial of ring vaccination (vaccinating contacts and contacts of contacts [CCCs] of index Ebola cases) which evaluated efficacy and safety of Ervebo in Guinea.
Protokol 010 (študija krožnega cepljenja) je bilo odprto, gručno randomizirano preskušanje 3. faze s krožnim cepljenjem (cepljenje kontaktov in kontaktov kontaktov [KKK]) indeksnih primerov obolelih za ebolo), ki je ovrednotila učinkovitost in varnost cepiva Ervebo v Gvineji.
The Full Analysis Set population was the primary population for the immunogenicity analyses in Protocols 009 and 011 and consists of all vaccinated subjects with serology data and had a serum sample collected within an acceptable day range.
Populacija celotnega nabora za analizo (FAS - full analysis set) je bila primarna populacija za analize imunogenosti v Protokolih 009 in 011; obsegala je vse cepljene preiskovance, ki so imeli serološke podatke in pri katerih je bil vzorec seruma odvzet v sprejemljivem razponu dni.
Across the Phase 1 through Phase 3 trials, 234 children and adolescents 6 to 17 years of age received a dose of Ervebo.
V preskušanjih od 1. do 3. faze je odmerek cepiva Ervebo prejelo 234 otrok in mladostnikov, starih od 6 do 17 let.
If you are not sure, talk to your healthcare worker.
Če ste negotovi, se posvetujte z zdravstvenim delavcem.
• Because Ervebo does not contain the whole Ebola virus, it cannot give you Ebola virus disease.
• Ker cepivo Ervebo ne vsebuje celih virusov, zaradi njega ne morete zboleti za ebolo.
Uncertainties remain as to the level, duration and type of protection given the methodological limitations and the exceptional circumstances experienced during the trial.
Glede na metodološke omejitve in izredne okoliščine, ki so vladale med preskušanjem, ostajajo raven, trajanje in vrsta zaščite negotove.
In different trials, rash was reported with median onsets of 7.5 to 10.5 days (range from 0 to 47 days).
V različnih preskušanjih, v katerih so poročali o izpuščajih, je bil mediani čas do njegovega nastopa od 7,5 do 10,5 dneva (v razponu od 0 do 47 dni).
• Basic hand hygiene
• osnovno higieno rok
• Safe sex
• varno spolnostjo
Rash was characterized in a variety of ways including generalized rash (2.3%), vesicular rash (0.5%), dermatitis (0.3%), or cutaneous vasculitis (0.01%) in clinical trials.
V kliničnih preskušanjih se je izpuščaj pojavil v različnih oblikah, vključno z generaliziranim izpuščajem (2,3 %), vezikularnim izpuščajem (0,5 %), dermatitisom (0,3 %) ali kožnim vaskulitisom (0,01 %).
Have a weak immune system
Če imate šibek imunski sistem
The MAH should develop and introduce an active substance in-process control for total protein with appropriate acceptance.
Imetnik dovoljenja za promet s cepivom mora v procesu izdelave učinkovine razviti in uvesti medprocesno kontrolo glede skupnih proteinov z ustrezno sprejemljivostjo preskusa.
Individuals who develop vesicular rash after receiving the vaccine should cover the vesicles until they heal to minimize the risk of possible transmission of vaccine virus through open vesicles.
Osebe, ki se jim po cepljenju pojavi vezikularen izpuščaj, morajo mehurčke pokrivati, dokler se ne pozdravijo, da bi tako zmanjšali možnost za prenos cepilnega virusa skozi odprte mehurčke.
Process and batch data from at least 3 representative FP batches should be provided.
Predložiti je treba procesne podatke in podatke serij vsaj 3 reprezentativnih serij učinkovine.
Vaccine virus RNA has been detected by PCR in the plasma of most of the adult subjects.
RNA cepilnega virusa so z verižno reakcijo s polimerazo (PCR - polymerase chain reaction) zaznali v plazmi večine odraslih preiskovancev.
Safety and efficacy of Ervebo have not been assessed in immunocompromised individuals.
Varnost in učinkovitost cepiva Ervebo pri imunsko oslabelih osebah nista ugotovljeni.
Use of Ervebo with other vaccines is not recommended.
Cepiva Ervebo ni priporočljivo uporabljati z drugimi cepivi.
This is because you could pass on the virus in the vaccine to them through your body fluids.
To je potrebno, ker viruse iz cepiva lahko prenesete nanje s svojimi telesnimi tekočinami.
As there are no data on co-administration of Ervebo with other vaccines, the concomitant use of Ervebo with other vaccines is not recommended.
O sočasni uporabi cepiva Ervebo z drugimi cepivi ni podatkov, zato sočasna uporaba cepiva Ervebo z drugimi cepivi ni priporočljiva.
• Avoid contact with bats and non-human primates or blood, fluids and raw meat prepared from these animals (bushmeat) or meat from an unknown source.
• izogibanjem stikom z netopirji in nehumanimi primati ter tudi stikom s krvjo, tekočinami in surovim mesom teh živali in z mesom neznanega izvora.
Vaccine virus might be present in biological fluids such as blood, urine, saliva, semen, vaginal fluids, aqueous humor, breast milk, faeces, sweat, amniotic fluid, and placenta.
Cepilni virus je lahko prisoten v bioloških tekočinah, kot so kri, urin, slina, seme, nožnična tekočina, očesna vodica, materino mleko, blato, znoj, amnijska tekočina in placenta.
Transient decreases in counts of lymphocytes, neutrophils and total white blood cells in the first 3 days following vaccination have been observed very commonly in Phase 1/2 studies; these events generally resolved after the first week post-vaccination.
faze so zelo pogosto opažali prehodno zmanjšanje števila limfocitov, nevtrofilcev in celotnega števila levkocitov v prvih 3 dneh po cepljenju; ti učinki so na splošno minili po prvem tednu po cepljenju.
However, once thawed, the vaccine can be stored for up to 14 days at 2°C to 8°C before use.
Toda ko je cepivo odtajano, ga je mogoče pred uporabo shranjevati do 14 dni pri temperaturi od 2 do 8 °C.
People catch Ebola from people or animals who are infected with Ebola or who died from Ebola.
Ljudje se bolezni ebola nalezejo od drugih ljudi s to boleznijo, od umrlih za to boleznijo, ali od živali, okuženih z njo.
The bandage may be removed when there is no visible fluid leakage.
Povoj lahko odstranite, ko ni vidnega izcejanja tekočine.
The surface protein of the virus has been replaced with that of Zaire Ebola Virus (rVSVΔG-ZEBOV-GP).
Beljakovina na površini virusa je nadomeščena z beljakovino virusa Ebola Zaire (rVSVΔG-ZEBOV-GP).
Summary of Geometric Mean Titers for the GP-ELISA from Protocols 009, 011 and 012 Clinical Trials
Povzetek geometrične sredine titrov za GP-ELISA iz kliničnih preskušanj Protokol 009, 011 in 012
Pregnancy should be avoided for 2 months following vaccination.
Ženska naj ne zanosi še 2 meseca po cepljenju.
Upon removal from the freezer, the product should be marked with both the date that it was taken out of the freezer and also a new discard date (in place of the labelled expiry date).
Po odstranitvi iz zmrzovalnika je treba označiti datum, ko je bilo cepivo vzeto iz zmrzovalnika, in novi datum, ko je cepivo treba zavreči (na mesto označenega roka uporabnosti).
• Put the used plasters and bandages in a sealed container, if possible, and throw them away in the garbage bin to avoid having animals come into contact with the plasters and bandages.
• Uporabljene obliže in povoje dajte v zapečaten vsebnik, če je to mogoče, in jih zavrzite v koš za smeti, da preprečite, da bi živali prišle v stik z obliži in povoji.
It is given as a single injection (dose of 1 mL) in the top of your arm or the outside of your thigh.
Dobili ga boste v enkratni injekciji (1-ml odmerek) v nadlaket ali v zunanji del stegna.
There is no need to use antimicrobial soaps for washing hands.
Umivanje rok s protimikrobnimi mili ni potrebno.
Immunization of subjects with the vaccine results in an immune response and protection from Zaire Ebola Virus Disease (EVD).
Cepljenje preiskovancev s tem cepivom je povzročilo imunski odziv in zaščito pred boleznijo zaradi virusa Ebola Zaire.
There are limited amount of data (less than 300 pregnancy outcomes) from the use of Ervebo in pregnant women, or women who became pregnant after receiving the vaccine.
Podatkov o uporabi cepiva Ervebo pri nosečnicah in ženskah, ki so zanosile po prejetju cepiva, je malo (manj kot 300 izidov nosečnosti).
When Ervebo was administered to female rats, antibodies against the vaccine virus were detected in foetuses and offspring, likely due to trans-placental transfer during gestation and with the acquisition of maternal antibodies during lactation, respectively (see section 4.6).
Ko je bilo cepivo Ervebo uporabljeno pri podganjih samicah, so pri plodovih in mladičih ugotovili protitelesa proti cepilnemu virusu, verjetno zaradi prenosa maternalnih protiteles skozi placento med brejostjo (pri plodovih) oz. z dojenjem (pri mladičih) (glejte poglavje 4.6).
If you think you might have a weak immune system, ask your healthcare worker if you should receive this vaccine.
Če menite, da imate šibek imunski sistem, se v primeru predvidenega cepljenja s tem cepivom posvetujte z zdravstvenim delavcem.
The safety of Ervebo has not been established in pregnant women.
Varnost cepiva Ervebo pri nosečnicah ni dokazana.
Continue to follow your healthcare worker's recommendations to protect yourself from Ebola infection after you get this vaccine.
Po opravljenem cepljenju še naprej upoštevajte navodila zdravstvenega delavca, da se boste zaščitili pred okužbo z virusom Ebola.
Concurrent illness
Sočasne bolezni
Store and transport frozen at -80°C to -60°C.
Shranjujte in prevažajte zmrznjeno pri temperaturi od -80 °C do -60 °C.
The preferred injection site is the deltoid area of the non-dominant arm or in the higher anterolateral area of the thigh.
Najbolje ga je injicirati v deltoidni predel nedominantne roke ali v zgornji anterolateralni predel stegna.
The preferred site is the deltoid area of the non-dominant arm or in the higher anterolateral area of the thigh.
Najbolje ga je aplicirati v deltoidni predel nedominantne roke ali v zgornji anterolateralni predel stegna.
Vaccination with Ervebo does not eliminate the necessity of standard precautions when caring for patients with known or suspected Ebola disease.
Cepljenje s cepivom Ervebo ne odpravlja potrebe po običajnih previdnostnih ukrepih v primeru nege bolnikov za katere je znano, da imajo ebolo, ali pri katerih obstaja sum nanjo.
Recombinant human serum albumin, trometamol buffer, water for injections, hydrochloric acid, sodium hydroxide
rekombinantni humani serumski albumin, trometamolijev pufer, voda za injekcije, klorovodikova kislina, natrijev hidroksid
• Upon removal from the freezer, the product should be marked with both the date that it was taken out of the freezer and also a new discard date (in place of the labelled expiry date).
• Po odstranitvi iz zmrzovalnika je treba označiti datum, ko je bilo cepivo vzeto iz zmrzovalnika, in novi datum, ko je cepivo treba zavreči (na mesto označenega roka uporabnosti).
Immunocompromised individuals may not respond as well as immunocompetent individuals to Ervebo.
Imunsko oslabele osebe se lahko na cepivo Ervebo ne odzovejo tako dobro kot imunsko sposobne.
Dispose of contaminated bandages following institutional guidelines or WHO healthcare waste management policy.
Kontaminirane povoje zavrzite v skladu s smernicami v ustanovi ali politiko Svetovne zdravstvene organizacije za ravnanje z zdravstvenimi odpadki.
Arthralgia was generally reported in the first few days following vaccination, was mild to moderate in intensity, and resolved within one week after onset.
O artralgiji so na splošno poročali v prvih nekaj dneh po cepljenju, bila je blaga do zmerna in je minila v enem tednu po pojavu.
Ervebo might make you bleed or bruise where the vaccine is injected.
Cepivo Ervebo namreč lahko povzroči krvavitev ali podplutbo na mestu, kjer je injicirano.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodiumfree'.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni ‘brez natrija'.
• Feeling tired,
• utrujenost
Ask your healthcare worker how to throw away medicines you no longer use.
O načinu odstranjevanja cepiva, ki ga ne uporabljate več, se posvetujte z zdravstvenim delavcem.
31 Jan 2020
31. januar 2020
The clinical development program included four Phase 2/3 (Protocols 009-012) clinical trials.
Program kliničnega razvoja je obsegal štiri klinična preskušanja 2./3.
• Store and transport frozen at -80°C to -60°C.
• Shranjujte in prevažajte zamrznjeno pri temperaturi od -80 °C do -60 °C.
Ervebo consists of a live, attenuated recombinant vesicular stomatitis virus-based vector expressing the envelope glycoprotein gene of Zaire Ebola virus (rVSVΔG-ZEBOV-GP).
Cepivo Ervebo vsebuje živ, oslabljen vektor na podlagi rekombinantnega virusa vezikularnega stomatitisa, ki ima izražen gen za glikoprotein ovojnice virusa Ebola Zaire (rVSVΔG-ZEBOV-GP).
Ervebo administered to female rats had no effects on mating performance, fertility, or embryonic/foetal development.
Cepivo Ervebo, uporabljeno pri podganjih samicah, ni vplivalo na sposobnost parjenja, plodnost ali razvoj zarodka/ploda.
It is unknown whether the vaccine virus is secreted in human milk.
Ni znano, ali se cepilni virus izloča v materino mleko.
• Ervebo is given to protect you from getting Ebola virus disease caused by the Zaire Ebola virus,
• Cepivo Ervebo uporabljamo, da bi vas pomagalo zaščititi pred ebolo, ki jo povzroča virus Ebola
In some people joint pain and swelling may come back after initially going away.
Nekaterim osebam se lahko bolečine v sklepih in oteklost sklepov ponovijo, potem ko so že minile.
Summary of Geometric Mean Titers for the PRNT from Protocols 009, 011 and 012 Clinical Trials
Povzetek geometrične sredine titrov za PRNT iz kliničnih preskušanj Protokol 009, 011 in 012
• You can catch Ebola from blood and body fluids like urine, stools, saliva, vomit, sweat, breast milk, semen and vaginal fluids of people who are infected with Ebola virus.
• Ebole se lahko nalezete preko krvi in telesnih tekočin, na primer urina, blata, sline, izbruhane vsebine, znoja, materinega mleka, semenske tekočine in nožničnih izločkov žensk, okuženih z virusom Ebola.
Pregnant and breast-feeding women
Nosečnice in doječe ženske
This product contains genetically modified organisms.
To zdravilo vsebuje gensko spremenjene organizme.
The other excipients are recombinant human serum albumin, trometamol buffer, water for injections, hydrochloric acid, sodium hydroxide.
Druge sestavine cepiva so rekombinantni humani serumski albumin, trometamolijev pufer, voda za injekcije, klorovodikova kislina, natrijev hidroksid.
CI = Confidence interval; GP-ELISA = Anti-Glycoprotein Human Enzyme-Linked Immunosorbent Assay (EU/mL); GMT = Geometric mean titer *Protocol 011 from Month 9-12
IZ = interval zaupanja, GP-ELISA = antiglikoproteinski humani encimskoimunski test (E.e./ml), GMT = geometrični srednji titer.
Put the used plasters and bandages in a sealed container, if possible, and throw them in the waste bin to to make sure that people with a weak immune system or animals do not come into contact with the plasters and bandages.
Uporabljene obliže in povoje dajte v zapečaten vsebnik, če je to mogoče, in jih zavrzite v koš za smeti, da zagotovite, da osebe s šibkim imunskim sistemom ali živali ne pridejo v stik z obliži in povoji.
• Keep the vial in the outer carton in order to protect from light.
• Viale shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
When Ervebo is administered to female rats, antibodies against the vaccine virus were detected in offspring, likely due to acquisition of maternal antibodies via placental transfer during gestation and via lactation.
Če je bilo cepivo Ervebo uporabljeno pri podganjih samicah, so pri mladičih ugotovili protitelesa proti cepilnemu virusu, verjetno zaradi pridobitve maternalnih protiteles skozi placento med brejostjo in z dojenjem.
The most common systemic adverse reactions reported following vaccination with Ervebo were headache (36.9%), pyrexia (34.3%), myalgia (32.5%), fatigue (18.5%), arthralgia (17.1%), nausea
Najpogostejši sistemski neželeni učinki, o katerih so poročali po cepljenju s cepivom Ervebo, so bili glavobol (36,9 %), zvišana telesna temperatura (34,3 %), mialgija (32,5 %), utrujenost (18,5 %), artralgija (17,1 %), navzea (8,0 %), mrzlica (6,3 %), artritis (3,7 %), izpuščaj (3,6 %), hiperhidroza (3,2 %) in bolečina v trebuhu (1,4 %).
No data are available for administration via the subcutaneous or intradermal routes.
Podatkov o subkutanem ali intradermalnem apliciranju ni.
live, attenuated) ≥72 million pfu Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP) Produced in Vero cells.
, z živimi oslabljenimi virusi) ≥ 72 milijonov pfu rekombinantni virus vezikularnega stomatitisa (rVSV) seva Indiana z delecijo glikoproteina (G) ovojnice VSV in njegovo nadomestitvijo s površinskim glikoproteinom (GP) virusa Ebola Zaire (ZEBOV - Zaire Ebola Virus) seva Kikwit 1995 pridobljeno v celicah Vero pfu = plakotvorne enote
Discard the vaccine if it is not used by the end of 14 days.
Če cepiva ne uporabite v 14 dneh, ga zavrzite.
The thawed vial should then be gently inverted several times prior to withdrawal with the syringe.
Odtajano vialo je treba pred odvzemom cepiva z brizgo večkrat previdno obrniti.
The vaccine virus RNA was detected in a skin vesicle at 12 days post-vaccination in one of the four subjects.
Pri enem od štirih preiskovancev so virusno RNA zaznali v kožnih mehurčkih 12 dni po cepljenju.
Protocol 012 Combined Consistency Lots Group
Združena skupina konsistenčnih serij
The MAH should provide additional data to confirm that the finished product (FP) process is properly validated.
Imetnik dovoljenja za promet s cepivom mora predložiti dodatne podatke, ki potrjujejo, da je postopek izdelave gotovega zdravila ustrezno validiran.
• generalized itching, redness, flushing or itchy bumps on the skin.
• po vsem telesu prisotno srbenje, pordelost, zardevanje ali srbeče bulice na koži.
Individuals administered Ervebo should not donate blood for at least 6 weeks post-vaccination.
Osebe, ki prejmejo cepivo Ervebo, vsaj 6 tednov po cepljenju ne smejo darovati krvi.
Cover the vaccination injection site or any vesicles with an adequate bandage (e.g. any adhesive bandage or gauze and tape) that provides a physical barrier to protect against direct contact (see sections 4.4 and 5.3).
Mesto injiciranja ali kakršne koli mehurčke na koži prekrijte z ustreznim povojem (npr. s kakršnim koli obližem ali gazo in trakom), ki zagotavlja fizično pregrado za zaščito pred neposrednim stikom (glejte poglavji 4.4 in 5.3).
Cover the vaccination site or any vesicles with an adequate bandage (e.g. any adhesive bandage or gauze and tape) that provides a physical barrier to protect against direct contact with vesicle fluid (see section 4.2).
Mesto cepljenja ali kakršne koli mehurčke na koži pokrijte z ustreznim povojem (npr. s kakršnim koli obližem ali gazo in trakom), ki zagotavlja fizično pregrado za zaščito pred neposrednim stikom s tekočino mehurčkov (glejte poglavje 4.2).
Talk to your healthcare worker before you receive Ervebo if you:
Preden prejmete cepivo Ervebo, se posvetujte z zdravstvenim delavcem, če:
Discard the vaccine if particulates are present.
Če so prisotni delci, cepivo zavrzite.
Cover the injection site with gauze or bandage (e.g. any adhesive bandage or gauze and tape) that provides a physical barrier to protect against direct contact with vesicle fluid.
Mesto injiciranja pokrijte z gazo ali povojem (npr. s kakršnim koli obližem ali gazo in trakom), ki zagotavlja fizično pregrado za zaščito pred neposrednim stikom s tekočino mehurčka.
High Dose Group
Skupina z velikim odmerkom
Standard precautions when caring for patients with known or suspected Ebola disease
Običajni previdnostni ukrepi pri oskrbi bolnikov, za katere je znano, da imajo ebolo, ali pri katerih obstaja sum nanjo
• Stomach pain,
• bolečine v trebuhu
Put the used plasters and bandages in a sealed container, if possible, and throw them away in the garbage bin to avoid having people with a weak immune system come into contact with the plasters and bandages.
Uporabljene obliže in povoje dajte v zapečaten vsebnik, če je to mogoče, in jih zavrzite v koš za smeti, da osebe s šibkim imunskim sistemom ne pridejo v stik z obliži in povoji.
• Any unused vaccine or waste material should be disposed of in compliance with the institutional guidelines for genetically modified organisms or biohazardous waste, as appropriate.
• Neuporabljeno cepivo ali odpadni material zavrzite v skladu s smernicami, ki v ustanovi veljajo za odpadke z genetsko spremenjenimi organizmi ali za biološko nevarne odpadke, kot je ustrezno.
Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP
cepivo proti virusu Ebola Zaire (rVSVΔG-ZEBOV-GP
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE UČINKOVINE (UČINKOVIN) IN PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
• Headache,
• glavobol
• Use alcohol-based hand sanitiser when hands are not dirty.
• Če roke niso umazane, uporabite sredstvo za čiščenje rok na osnovi alkohola.
Solution for injection The solution is a colourless to slightly brownish-yellow liquid.
raztopina za injiciranje Raztopina je brezbarvna do rahlo rjavorumena tekočina.
• You may test positive for Ebola virus after you receive Ervebo.
• Potem ko ste prejeli cepivo Ervebo, imate lahko pozitiven izvid testa za ebolo.
• Contact with blood and body fluids (such as urine, faeces, saliva, sweat, vomit, breast milk,
• Stiku s krvjo in telesnimi tekočinami (na primer z urinom, blatom, slino, znojem, izbruhano vsebino, materinim mlekom, semensko in nožnično tekočino).
Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity and toxicity to reproduction and development.
Predklinični podatki na osnovi običajnih študij toksičnosti pri ponavljajočih odmerkih in vpliva na sposobnost razmnioževanja in razvoja ne kažejo posebnega tveganja za človeka.
Individuals who develop vesicular rash after receiving the vaccine should cover the vesicles until they heal.
Osebe, ki se jim po cepljenju pojavi vezikularen izpuščaj, morajo mehurčke pokrivati, dokler se ne pozdravijo.
How to store Ervebo
Kako boste prejeli cepivo Ervebo
This vaccine will not protect you against the other types of Ebola virus.
Zaire, vrsta virusa Ebola.To cepivo vas ne bo zaščitilo pred drugimi vrstami virusov Ebola.
Vaccine recipients should attempt to avoid exposure of livestock to blood and bodily fluids for at least 6 weeks following vaccination.
Prejemniki cepiva naj se vsaj 6 tednov po cepljenju poskusijo izogibati izpostavljanju živine krvi in telesnim tekočinam.
In a small number of subjects, the vaccine virus was recovered from joint effusion samples, suggestive of a virally-mediated process postvaccination.
Pri majhnem številu preiskovancev so v vzorcih sklepnega izliva našli cepilni virus; to kaže na virusno pogojeno dogajanje po cepljenju.
• If you get any side effects, talk to your healthcare worker.
• Če opazite kateri koli neželeni učinek, se posvetujte z zdravstvenim delavcem.
Vaccine recipients should avoid close contact with and exposure of high-risk individuals to blood and bodily fluids for at least 6 weeks following vaccination.
Prejemniki cepiva naj se vsaj 6 tednov po cepljenju izogibajo tesnemu stiku z osebami, ki imajo veliko tveganje, in izpostavljanju takšnih oseb krvi ali telesnim tekočinam.
Water for injections Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment)
6.1 Seznam pomožnih snovi rekombinantni humani serumski albumin trometamolijev pufer voda za injekcije klorovodikova kislina (za prilagoditev pH) natrijev hidroksid (za prilagoditev pH)
• Safe burial practices
• varnimi postopki pokopa